Rex Fang & Innovation Equity Premium Income ETF vs Oscar Health Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while Oscar Health Inc trades at $33.4 (market cap $10.22B). The key difference: Oscar Health Inc is far larger — about 13.7× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Oscar Health Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Oscar Health Inc for 15 Days on average.
| FEPI | OSCR | |
|---|---|---|
Market Cap | $746.48M | $10.22B |
Volume | 334,337 | 4,123,394 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $33.81 |
52-Week Low | $37.98 | $10.85 |
Typical Hold Time | 56 Days | 15 Days |
Enterprise Value | — | $6.57B |
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.51, down 0.18% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on concentrated AI and mega-cap tech holdings, generating high weekly distributions averaging $0.20-0.21. Recent articles highlight its 25% trailing yield but note capped upside potential and underperformance versus peers in total return during tech rallies.
The outlook balances high income generation against significant risk from tech concentration and volatility dependence. While the covered call strategy funds substantial dividends, it limits capital appreciation during market upswings. Key risks include drawdown vulnerability if tech stocks decline and competitive pressure from higher-performing income alternatives. Analyst sentiment remains cautious due to the trade-off between yield and total return potential.
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →